Can Artiva Biotherapeutics, Inc. turn deep B-cell depletion into a scalable autoimmune treatment model?
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.
Pharma & Biotech
Pharma & Biotech
Merck may have solved the hidden problem behind the oral PCSK9 race
Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.
Pharma & Biotech
Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform
Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.
Pharma & Biotech
Is Zentalis Pharmaceuticals, Inc. on track for accelerated approval in ovarian cancer
Can azenosertib secure accelerated approval? Explore how Zentalis Pharmaceuticals, Inc.’s trials could reshape ovarian cancer treatment.
Pharma & Biotech
What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment
Can Madrigal Pharmaceuticals, Inc. reshape MASH treatment with ARO-PNPLA3? Discover what this precision strategy means for the future.
Pharma & Biotech
What BridgeBio Pharma, Inc.’s latest data signals for the future of targeted endocrine therapies
Explore how BridgeBio Pharma, Inc.’s Phase 3 CALIBRATE data could transform ADH1 treatment and reshape rare endocrine care. Read more now.
Pharma & Biotech
Could LANGLARA finally crack the high-cost insulin access problem in the United States?
Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.
Pharma & Biotech
Rezolute’s ersodetug data deepens the congenital hyperinsulinism regulatory debate
Rezolute, Inc. has presented expanded Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, adding continuous glucose monitoring outcomes and open-label extension observations to a program that previously missed its primary endpoint. The update places the late-stage rare disease biotech firm in a complex regulatory position, as the
Pharma & Biotech
Could BioCardia, Inc.’s integrated platform overcome variability in cardiac regenerative treatments
Discover how BioCardia, Inc.’s Heart3D platform could reduce variability in cardiac cell therapy. Read the full analysis on what this means next.
Pharma & Biotech
What TG Therapeutics, Inc.’s AAN 2026 updates reveal about real-world performance of BRIUMVI in multiple sclerosis
Explore how TG Therapeutics, Inc.’s BRIUMVI data at AAN 2026 could reshape real-world MS treatment and adoption trends. Read the full analysis now.